论文部分内容阅读
BM06002是一个新合成药(化学名:4-亚胺-1.3二氮二环己烷)。动物实验已证明有刺激体液性及细胞性免疫反应的作用,并抑制小鼠实验性肿瘤的生长。给病人静注20、80及100mg均未见毒副作用。因此作者选择6例晚期肿瘤病人应用此药,以观察有否刺激人体免疫反应作用。 6例病人中2例为乳腺癌,3例肺癌,1例黑色素瘤。均为外科与化疗或放射治疗后复发的病人。给药前作下列免疫学试验:结核菌素、链激道酶(Varidase)、腮腺炎抗原、胞浆毒素及念珠菌素的迟发性过敏反应,并用二硝基氯苯使病人致敏。应用一剂
BM06002 is a new synthetic drug (chemical name: 4-imine-1.3 diazabicyclohexane). Animal experiments have shown to stimulate the humoral and cellular immune response and inhibit the growth of mouse experimental tumors. The patient intravenous injection of 20,80 and 100mg were not seen toxic side effects. Therefore, the author chose 6 patients with advanced cancer patients to use this drug to observe whether the role of stimulating the body’s immune response. Two of the six patients had breast cancer, three had lung cancer, and one had melanoma. All patients were surgical and chemotherapy or recurrence after radiotherapy. The following immunological tests were performed prior to dosing: delayed allergic reactions to tuberculin, Varidase, mumps antigens, cytoplasmic toxins and candida and sensitized to patients with dinitrochlorobenzene. Apply a dose